Naloxon Accord (Naloxone Hydrochloride)

Naloxone, the active ingredient in Naloxon Accord, is an opioid antagonist presented as a sterile solution for intramuscular and intravenous use. It rapidly reverses opioid‑induced respiratory depression and other life‑threatening effects in patients who have taken an opioid overdose.

GNH USA supplies Naloxon Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets EU quality standards, is manufactured under strict GMP conditions, and is available for global distribution.

Naloxone acts on the opioid system to counteract life‑threatening overdose effects.

Opioid overdose: restores normal breathing and consciousness in patients experiencing respiratory depression due to excess opioids. Opioid toxicity: reverses central nervous system depression caused by opioid intoxication. Opioid‑induced respiratory depression: rapidly improves oxygenation and ventilation in emergency settings.

Adverse reactions may occur following administration of naloxone.

Common Side Effects: - Nausea - Vomiting - Sweating - Tachycardia - Hypertension - Headache

Serious or Rare Side Effects: - Seizures - Cardiac arrhythmias - Pulmonary edema - Anaphylactic reaction - Severe hypertension - Acute opioid withdrawal syndrome

Naloxon Accord should be used with careful clinical assessment and monitoring. - Verify opioid exposure: confirm recent opioid use before administration. - Monitor respiratory status: observe breathing rate and oxygen saturation after dosing. - Watch for acute withdrawal: be prepared to manage agitation, pain, or hypertension in opioid‑dependent patients. - Avoid intravascular injection: ensure proper intramuscular or subcutaneous technique. - Pregnancy and lactation: use only if the benefit outweighs potential risk, as safety data are limited. - Store at ambient temperature: keep in the original container, protect from light and moisture.

Naloxone may interact with other drugs that affect the central nervous system or cardiovascular function.

Major Interactions (Avoid): - Mixed agonist‑antagonist opioids (e.g., buprenorphine): may reduce naloxone efficacy. - Monoamine oxidase inhibitors: risk of hypertensive crisis when combined. - Potent sympathomimetic agents: may exacerbate cardiovascular effects.

Moderate Interactions (Monitor Closely): - Benzodiazepines or other sedatives: monitor for additive CNS depression. - Alcohol: increased risk of respiratory compromise. - Antihypertensive medications: naloxone‑induced hypertension may mask therapeutic effects.